Menu
Recruiting NCT07178509

A Study of SCAD Using Stress Contrast Echocardiography

— Observational Spontaneous Coronary Artery Dissection

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Stress Echocardiography with Contrast.
Who it may be relevant to
Registry conditions: Spontaneous Coronary Artery Dissection. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Myocardial Perfusion in Spontaneous Coronary Artery Dissection Using Stress Contrast Echocardiography

Overview

This study aims to fill knowledge gaps regarding microvascular perfusion and pressor response to stress among patients with history of spontaneous coronary artery dissection (SCAD) using stress contrast echocardiography.

Interventions

  • Procedure Stress Echocardiography with Contrast
    Stress Echocardiography with Contrast will be used to assess heart function and blood flow response to stressors.

Primary outcome measures

  • Change in Microvascular Function [Time frame: Baseline, immediately after the Stress Echocardiography]
  • Change in Blood Pressure [Time frame: Baseline, immediately after the Stress Echocardiography]
  • Change in Heart Rate [Time frame: Baseline, immediately after the Stress Echocardiography]

Eligibility criteria

Inclusion criteria

  • Adult >18 years old
  • Patient has a history of spontaneous coronary artery dissection (SCAD) OR patient is healthy with no significant medical history

Exclusion criteria

  • Unable to give consent
  • Allergic or have a history of adverse reaction to dobutamine, the Definity® ultrasound enhancing agent, or atropine.
  • Has a known or suspected hypersensitivity to perflutren and therefore cannot be given Definity®.
  • Pregnant.
  • Unable to interrupt breastfeeding.
  • Within 3 months of a heart attack.
  • Severe aortic stenosis.
  • Severe, uncontrolled hypertension (>200/110 mmHg at baseline).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Case-control

Study locations

United States · 1 center
  • Mayo Clinic — Rochester

Identifiers

NCT: NCT07178509 · 24-002318 · 1K23HL155506

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗